Skip to main content
Premium Trial:

Request an Annual Quote

CST, AstraZeneca Ink Third Phosphorylation-Profiling Deal

NEW YORK, April 12 (GenomeWeb News) - Cell Signaling Technology has signed a third agreement with AstraZeneca to continue providing the drug maker with phosphorylation profiles and prospective biomarkers of kinase-targeted lead compounds, the company said today.

 

CST announced similar agreements this January and in June 2004.

 

According to its most recent statement, it will use its PhosphoScan technology to provide AstraZeneca with information that could enable it to clinically develop biomarker assays for target validation and therapeutic kinase inhibitors.

 

CST also said that it has recently added methods for serine/threonine kinase PhosphoScan profiling to its capabilities.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.